Description
PNC-27 is an experimental 32-residue anti-cancer peptide, often supplied as a 10 mg or 5 mg lyophilized powder, designed to selectively kill cancer cells by binding to HDM-2 on their membranes, creating pores that cause cell lysis
. It targets tumor cells without affecting normal cells and is studied for treating solid tumors.
Key Aspects of PNC-27
- Mechanism of Action: Derived from the p53 tumor-suppressor protein, PNC-27 binds to HDM-2 (human double minute-2) protein found specifically on the plasma membranes of cancer cells, forcing them to undergo necrosis.
- Selectivity: It acts selectively, killing leukemia, pancreatic, and melanoma cell lines in studies, without affecting normal cells, as documented in preclinical studies.
- Components: It consists of a p53 residues 12–26 binding domain and a membrane-penetrating peptide sequence.
- Usage Limitations: The FDA has not evaluated or approved PNC-27 as safe or effective for treating any disease, and it is largely used in research settings.
Formulation: It is frequently supplied as a synthetic peptide (often >80–95% purity) requiring reconstitution for laboratory use, sometimes studied with solvents like sterile water or buffer solutions.
patients reach and maintain lower HbA1c and weight levels.
Disclaimer: This information is for educational purposes based on research studies and does not constitute medical advice. Consult a healthcare provider before starting any peptide therapy.
Reviews
There are no reviews yet.